Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Catherine S. Forster is active.

Publication


Featured researches published by Catherine S. Forster.


Nature Medicine | 2011

The Ngal reporter mouse detects the response of the kidney to injury in real time

Neal Paragas; Andong Qiu; Qing-Yin Zhang; Benjamin Samstein; Shixian Deng; Kai M. Schmidt-Ott; Melanie Viltard; Wenqiang Yu; Catherine S. Forster; Gangli Gong; Yidong Liu; Ritwij Kulkarni; Kiyoshi Mori; Avtandil Kalandadze; Adam J. Ratner; Prasad Devarajan; Donald W. Landry; Chyuan-Sheng Lin; Jonathan Barasch

Many proteins have been proposed to act as surrogate markers of organ damage, yet for many candidates the essential biomarker characteristics that link the protein to the injured organ have not yet been described. We generated an Ngal reporter mouse by inserting a double-fusion reporter gene encoding luciferase-2 and mCherry (Luc2-mC) into the Ngal (Lcn2) locus. The Ngal-Luc2-mC reporter accurately recapitulated the endogenous message and illuminated injuries in vivo in real time. In the kidney, Ngal-Luc2-mC imaging showed a sensitive, rapid, dose-dependent, reversible, and organ- and cell-specific relationship with tubular stress, which correlated with the level of urinary Ngal (uNgal). Unexpectedly, specific cells of the distal nephron were the source of uNgal. Cells isolated from Ngal-Luc2-mC mice also revealed both the onset and the resolution of the injury, and the actions of NF-κB inhibitors and antibiotics during infection. Thus, imaging of Ngal-Luc2-mC mice and cells identified injurious and reparative agents that affect kidney damage.


Journal of the American College of Cardiology | 2012

Diagnostic and Prognostic Stratification in the Emergency Department Using Urinary Biomarkers of Nephron Damage: A Multicenter Prospective Cohort Study

Thomas L. Nickolas; Kai M. Schmidt-Ott; Pietro A. Canetta; Catherine S. Forster; Eugenia Singer; Meghan E. Sise; Antje Elger; Omar H. Maarouf; David Sola-Del Valle; Matthew O'Rourke; Evan Sherman; Peter Lee; Abdallah Geara; Philip Imus; Achuta Guddati; Allison Polland; Wasiq Rahman; Saban Elitok; Nasir Malik; James Giglio; Suzanne El-Sayegh; Prasad Devarajan; Sudarshan Hebbar; Subodh J. Saggi; Barry Hahn; Ralph Kettritz; Friedrich C. Luft; Jonathan Barasch

OBJECTIVES This study aimed to determine the diagnostic and prognostic value of urinary biomarkers of intrinsic acute kidney injury (AKI) when patients were triaged in the emergency department. BACKGROUND Intrinsic AKI is associated with nephron injury and results in poor clinical outcomes. Several urinary biomarkers have been proposed to detect and measure intrinsic AKI. METHODS In a multicenter prospective cohort study, 5 urinary biomarkers (urinary neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, urinary liver-type fatty acid binding protein, urinary interleukin-18, and cystatin C) were measured in 1,635 unselected emergency department patients at the time of hospital admission. We determined whether the biomarkers diagnosed intrinsic AKI and predicted adverse outcomes during hospitalization. RESULTS All biomarkers were elevated in intrinsic AKI, but urinary neutrophil gelatinase-associated lipocalin was most useful (81% specificity, 68% sensitivity at a 104-ng/ml cutoff) and predictive of the severity and duration of AKI. Intrinsic AKI was strongly associated with adverse in-hospital outcomes. Urinary neutrophil gelatinase-associated lipocalin and urinary kidney injury molecule 1 predicted a composite outcome of dialysis initiation or death during hospitalization, and both improved the net risk classification compared with conventional assessments. These biomarkers also identified a substantial subpopulation with low serum creatinine at hospital admission, but who were at risk of adverse events. CONCLUSIONS Urinary biomarkers of nephron damage enable prospective diagnostic and prognostic stratification in the emergency department.


Journal of Clinical Investigation | 2014

α–Intercalated cells defend the urinary system from bacterial infection

Neal Paragas; Ritwij Kulkarni; Max Werth; Kai M. Schmidt-Ott; Catherine S. Forster; Rong Deng; Qing-Yin Zhang; Eugenia Singer; Alexander D. Klose; Tian Huai Shen; Kevin P. Francis; Sunetra Ray; Soundarapandian Vijayakumar; Samuel Seward; Mary E. Bovino; Katherine Xu; Yared Takabe; Fábio E. Amaral; Sumit Mohan; Rebecca Wax; Kaitlyn Corbin; Simone Sanna-Cherchi; Kiyoshi Mori; Lynne L. Johnson; Thomas L. Nickolas; Vivette D. D’Agati; Chyuan-Sheng Lin; Andong Qiu; Qais Al-Awqati; Adam J. Ratner

α-Intercalated cells (A-ICs) within the collecting duct of the kidney are critical for acid-base homeostasis. Here, we have shown that A-ICs also serve as both sentinels and effectors in the defense against urinary infections. In a murine urinary tract infection model, A-ICs bound uropathogenic E. coli and responded by acidifying the urine and secreting the bacteriostatic protein lipocalin 2 (LCN2; also known as NGAL). A-IC-dependent LCN2 secretion required TLR4, as mice expressing an LPS-insensitive form of TLR4 expressed reduced levels of LCN2. The presence of LCN2 in urine was both necessary and sufficient to control the urinary tract infection through iron sequestration, even in the harsh condition of urine acidification. In mice lacking A-ICs, both urinary LCN2 and urinary acidification were reduced, and consequently bacterial clearance was limited. Together these results indicate that A-ICs, which are known to regulate acid-base metabolism, are also critical for urinary defense against pathogenic bacteria. They respond to both cystitis and pyelonephritis by delivering bacteriostatic chemical agents to the lower urinary system.


Kidney International | 2012

NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease

Thomas L. Nickolas; Catherine S. Forster; Meghan E. Sise; Nicholas Barasch; David Sola-Del Valle; Melanie Viltard; Charles Buchen; Shlomo Kupferman; Maria Luisa Carnevali; Michael Bennett; Silvia Mattei; Achiropita Bovino; Lucia Argentiero; Andrea Magnano; Prasad Devarajan; Kiyoshi Mori; Hediye Erdjument-Bromage; Paul Tempst; Landino Allegri; Jonathan Barasch

The rate of progression of chronic kidney disease (CKD) is difficult to predict using single measurements of serum creatinine or proteinuria. On the other hand, documented tubulointerstitial disease presages worsening CKD, but kidney biopsy is not practical for routine use and generally does not sample the tubulointerstitial compartment of the medulla. Perhaps a urine test that correlates with specific histological findings may serve as a surrogate for the kidney biopsy. Here we compared both immunoblot analysis (under non-reducing conditions) and a commercially available monomer immunoassays of Neutrophil Gelatinase Associated Lipocalin (NGAL) with pathological changes found in kidney biopsies, to determine whether specific histological characteristics associated with a specific NGAL species. We found that the urine of patients with advanced CKD contained NGAL monomers as well as higher molecular weight complexes containing NGAL, identified by MALDI-TOF/TOF mass spectroscopy. The NGAL monomer significantly correlated with glomerular filtration rate, interstitial fibrosis and tubular atrophy. Hence, specific assays of the NGAL monomer implicate histology associated with progressive, severe CKD.The type and the extent of tissue damage inform the prognosis of chronic kidney disease (CKD), but kidney biopsy is not a routine test. Urinary tests that correlate with specific histological findings might serve as surrogates for the kidney biopsy. We used immunoblots and ARCHITECT-NGAL assays to define the immunoreactivity of urinary neutrophil gelatinase-associated lipocalin (NGAL) in CKD, and we used mass spectroscopy to identify associated proteins. We analyzed kidney biopsies to determine whether specific pathological characteristics associated with the monomeric NGAL species. Advanced CKD urine contained the NGAL monomer as well as novel complexes of NGAL. When these species were separated, we found a significant correlation between the NGAL monomer and glomerular filtration rate (r=-0.53, P<0.001), interstitial fibrosis (mild vs. severe disease; mean 54 vs. 167 μg uNGAL/g Cr, P<0.01), and tubular atrophy (mild vs. severe disease; mean 54 vs. 164 μg uNGAL/g Cr, P<0.01). Monospecific assays of the NGAL monomer demonstrated a correlation with histology that typifies progressive, severe CKD.


Journal of The American Society of Nephrology | 2009

Urinary NGAL Marks Cystic Disease in HIV-Associated Nephropathy

Neal Paragas; Thomas L. Nickolas; Christina M. Wyatt; Catherine S. Forster; Meghan E. Sise; Susan Morgello; Bernd Jagla; Charles Buchen; Peter Stella; Simone Sanna-Cherchi; Maria Luisa Carnevali; Silvia Mattei; Achiropita Bovino; Lucia Argentiero; Andrea Magnano; Prasad Devarajan; Kai M. Schmidt-Ott; Landino Allegri; Paul E. Klotman; Ali G. Gharavi; Jonathan Barasch

Nephrosis and a rapid decline in kidney function characterize HIV-associated nephropathy (HIVAN). Histologically, HIVAN is a collapsing focal segmental glomerulosclerosis with prominent tubular damage. We explored the expression of neutrophil gelatinase-associated lipocalin (NGAL), a marker of tubular injury, to determine whether this protein has the potential to aid in the noninvasive diagnosis of HIVAN. We found that expression of urinary NGAL was much higher in patients with biopsy-proven HIVAN than in HIV-positive and HIV-negative patients with other forms of chronic kidney disease. In the HIV-transgenic mouse model of HIVAN, NGAL mRNA was abundant in dilated, microcystic segments of the nephron. In contrast, urinary NGAL did not correlate with proteinuria in human or in mouse models. These data show that marked upregulation of NGAL accompanies HIVAN and support further study of uNGAL levels in large cohorts to aid in the noninvasive diagnosis of HIVAN and screen for HIVAN-related tubular damage.


Journal of Cardiac Surgery | 2006

Effect of Donor Age on Long-Term Survival Following Cardiac Transplantation

V.K. Topkara; Faisal H. Cheema; Satish Kesavaramanujam; Michelle L. Mercando; Catherine S. Forster; Michael Argenziano; Barry C. Esrig; Mehmet C. Oz; Yoshifumi Naka

Abstract  Background and Aim: The current shortage of donor hearts has forced the criteria of organ procurement to be extended, leading to increased use of older donor hearts to bridge the gap between demand and availability. Our objective was to analyze the effect of donor age on outcomes after cardiac transplantation. Methods: We retrospectively studied 864 patients who underwent cardiac transplantation at New York Presbyterian Hospital – Columbia University between 1992 and 2002. Patients were divided into two groups; donor age <40 years (Group A, n = 600) and donor age ≥40 years (Group B, n = 264). Results: Characteristics including gender, body mass index, and cytomegalovirus (CMV) status were significantly different between the two donor age groups. Race, CMV status, toxoplasmosis status, left ventricular assist device prior to transplant, diabetes mellitus, and retransplantation were similar in both the recipient groups, while age, gender, and BMI were different. Early mortality was lower in Group A, 5%, versus 9.5% in Group B. Multivariate analysis revealed recipient female gender (odd ratio (OR) = 1.71), retransplantation (OR = 1.63), and increased donor age (OR = 1.02) as significant predictors of poor survival in the recipient population. Actuarial survival at 1 year (86.7% vs 81%), 5 years (75% vs 65%), and 10 years (56% vs 42%) was significantly different as well with a log rank p = 0.002. Conclusions: These findings suggest that increased donor age is an independent predictor of long‐term survival. However, the shortage of organs makes it difficult to follow strict guidelines when placing hearts; therefore, decisions need to be made on a relative basis.


Journal of The American Society of Nephrology | 2017

Unique Transcriptional Programs Identify Subtypes of AKI.

Katherine Xu; Paul Rosenstiel; Neal Paragas; Christian Hinze; Xiaobo Gao; Tian Huai Shen; Max Werth; Catherine S. Forster; Rong Deng; Efrat Bruck; Roger W. Boles; Alexandra Tornato; Tejashree Gopal; Madison Jones; Justin Konig; Jacob Stauber; Vivette D. D’Agati; Hediye Erdjument-Bromage; Subodh J. Saggi; Gebhard Wagener; Kai M. Schmidt-Ott; Nicholas Tatonetti; Paul Tempst; Juan A. Oliver; Paolo Guarnieri; Jonathan Barasch

Two metrics, a rise in serum creatinine concentration and a decrease in urine output, are considered tantamount to the injury of the kidney tubule and the epithelial cells thereof (AKI). Yet neither criterion emphasizes the etiology or the pathogenetic heterogeneity of acute decreases in kidney excretory function. In fact, whether decreased excretory function due to contraction of the extracellular fluid volume (vAKI) or due to intrinsic kidney injury (iAKI) actually share pathogenesis and should be aggregated in the same diagnostic group remains an open question. To examine this possibility, we created mouse models of iAKI and vAKI that induced a similar increase in serum creatinine concentration. Using laser microdissection to isolate specific domains of the kidney, followed by RNA sequencing, we found that thousands of genes responded specifically to iAKI or to vAKI, but very few responded to both stimuli. In fact, the activated gene sets comprised different, functionally unrelated signal transduction pathways and were expressed in different regions of the kidney. Moreover, we identified distinctive gene expression patterns in human urine as potential biomarkers of either iAKI or vAKI, but not both. Hence, iAKI and vAKI are biologically unrelated, suggesting that molecular analysis should clarify our current definitions of acute changes in kidney excretory function.


PLOS ONE | 2017

Does NGAL reduce costs? A cost analysis of urine NGAL (uNGAL) & serum creatinine (sCr) for acute kidney injury (AKI) diagnosis

Amay Parikh; John A. Rizzo; Pietro A. Canetta; Catherine S. Forster; Meghan E. Sise; Omar H. Maarouf; Eugenia Singer; Antje Elger; Saban Elitok; Kai M. Schmidt-Ott; Jonathon Barasch; Thomas L. Nickolas

Introduction Urine neutrophil gelatinase-associated lipocalin (uNGAL) is a sensitive and specific diagnostic test for acute kidney injury (AKI) in the Emergency Department (ED), but its economic impact has not been investigated. We hypothesized that uNGAL used in combination with serum creatinine (sCr) would reduce costs in the management of AKI in patients presenting to the ED in comparison to using sCr alone. Materials and methods A cost simulation model was developed for clinical algorithms to diagnose AKI based on sCr alone vs. uNGAL plus sCr (uNGAL+sCr). A cost minimization analysis was performed to determine total expected costs for patients with AKI. uNGAL test characteristics were validated with eight-hundred forty-nine patients with sCr ≥1.5 from a completed study of 1635 patients recruited from EDs at two U.S. hospitals from 2007–8. Biomarker test, AKI work-up, and diagnostic imaging costs were incorporated. Results For a hypothetical cohort of 10,000 patients, the model predicted that the expected costs were


Nephrology Dialysis Transplantation | 2011

Urine neutrophil gelatinase-associated lipocalin identifies unilateral and bilateral urinary tract obstruction

Meghan E. Sise; Catherine S. Forster; Eugenia Singer; David Sola-Del Valle; Barry Hahn; Kai M. Schmidt-Ott; Jonathan Barasch; Thomas L. Nickolas

900 per patient (pp) in the sCr arm and


Pediatric Nephrology | 2017

Neutrophil gelatinase-associated lipocalin: utility in urologic conditions

Catherine S. Forster; Prasad Devarajan

950 in the uNGAL+sCr arm. uNGAL+sCr resulted in 1,578 fewer patients with delayed diagnosis and treatment than sCr alone (2,013 vs. 436 pts) at center 1 and 1,973 fewer patients with delayed diagnosis and treatment than sCr alone at center 2 (2,227 vs. 254 patients). Although initial evaluation costs at each center were

Collaboration


Dive into the Catherine S. Forster's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Thomas L. Nickolas

Columbia University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Kai M. Schmidt-Ott

Max Delbrück Center for Molecular Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Elizabeth Jackson

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Prasad Devarajan

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

David Sola-Del Valle

Massachusetts Eye and Ear Infirmary

View shared research outputs
Top Co-Authors

Avatar

Eugenia Singer

Max Delbrück Center for Molecular Medicine

View shared research outputs
Top Co-Authors

Avatar

Stuart L. Goldstein

Cincinnati Children's Hospital Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge